ORAL-B
Oral-B, a leading innovator in oral health is on a mission to change this with the launch of THE BIG RETHINK, its social ambition to ensure that everybody has an equitable oral care experience - whether that’s at home or in the dentist’s chair. The brand, who is at the beginning of this journey recognizes the need to continue learning from both dental professionals and consumers who frequently experience oral health struggles to be able to make a real impact and offer an equitable oral care experience for everyone.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006117/en/
Oral-B launches The Big Rethink initiative at exclusive launch event in Frankfurt with panel of experts on how to make oral care more inclusive and accessible. Pictured (left to right): British broadcaster, Nikki Fox, Executive Board Member of the iADH, Alison Dougall, British influencer James Hunt from Stories About Autism, iADH spokesperson, Johanna Norderyd, popular German actor, Andre Dietz, Chief Executive Officer for Healthcare, Jennifer Davis and P&G Europe Oral Care Senior Vice President, Benjamin Binot. (Photo: Business Wire)
To launch THE BIG RETHINK campaign, the brand is working together with the International Association for Disability and Oral Health (iADH) to help inform the approach. The first step of this partnership is the launch of the ‘Positive Practices’ programme, designed to train and educate dental practices on how to become more confident and inclusive when it comes to their patients. The programme will not only enable Oral-B to become more educated on the physical and mental needs of those with different types of disabilities, but it will also help them to learn how to adapt their product offering and improve the oral health outcomes of those with disabilities. THE BIG RETHINK Content Hub will also offer relevant and helpful content for people with disabilities, their caregivers and families, as well as the professional dental health community. Visit: https://www.oralb.co.uk/en-gb/big-rethink.
As Oral-B celebrates 60 years since the launch of the first electric toothbrush in 1963, the brand continues to put consumer understanding and leading-edge technology at the heart of its product development by designing inclusive products that help to bring about positive change in oral care for everyone. The brand is also developing a series of tools to support dentists within their practices, such as student training and accreditation programmes.
To celebrate the launch of THE BIG RETHINK, a brand film was unveiled last night at an exclusive launch event in Frankfurt, Germany. The event was an opportunity for Oral-B to set out its ambitions of THE BIG RETHINK and discuss the findings of The Oral Health & Disability European Study with an influential panel of speakers. Including P&G’s Chief Executive Officer for Healthcare, Jennifer Davis, iADH spokesperson, Johanna Norderyd, British broadcaster, Nikki Fox, British influencer James Hunt from Stories About Autism and popular German actor, Andre Dietz.
Jennifer Davis, P&G Chief Executive Officer, Healthcare says: “As a leading innovator in oral health for over 70 years and the world’s #1 dentist recommended toothbrush brand, we recognise the importance of making oral care accessible to all. We are indeed at the beginning of a very exciting journey, and we will continue to learn from both dental professionals and consumers to ensure we are creating positive oral care solutions for everyone – I really believe that this is the beginning of an initiative that has a global footprint.”
Benjamin Binot, P&G Europe Oral Care Senior Vice President comments: “Addressing the significant oral health inequalities experienced by people with disabilities in Europe is a huge priority for Oral-B. Our research shows that today, there are many oral health struggles amongst this audience – 1 in 5 (20%) of those with severe disabilities find brushing all their teeth physically challenging* and over a third of people with disabilities feel anxious or frustrated when it comes to visiting the dentist*. We want to help change this and believe that everyone should have an equitable oral health experience. Through our work with the iADH and the creation of the Positive Practices programme, we want to not only provide dental practices with educational materials to make their practices more inclusive, but also give the disabled community the tools they need to have more autonomy over their own oral health.
Alison Dougall, Professor in Special Care Dentistry, and an Executive Board member of iADH says; “We are delighted to have partnered with Oral-B to address the oral health struggles that are experienced by people with disabilities in Europe. Our shared values will enable us to make a huge difference to the oral care experience for people living with visible and nonvisible disabilities. We recognise that many healthcare professionals have not received education in special care dentistry during their training, and so by raising awareness around the issue and supporting those with disabilities, we can help to make small but significant adjustments to their oral health routines.”
-ENDS-
About Oral-B
Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.
About the research
– The Oral Health & Disability European Study – UK, France, Germany and Italy, was conducted by Reputation Leaders.
– The studies were conducted between 2021 – 2022 in Germany (n=1034), France (n=1009), UK (n=2029) and Italy (n=1002). In each country the online survey sample was recruited and reported to be representative of the total adult population by age, gender and region.
– The margin of error of a sample of 5000 adults is +/- 1.4% at a 95% confidence level for the 4 leading economies.
– At a country level, the margin of error of the sample relative to the total adult population was UK n=2000 (+/- 2.2%), Germany, France and Italy, n=1000 (+/- 3.1%)
+ Assumes total EU and UK population, 2022
About The iADH (International Association for Disability and Oral Health)
The iADH is a global organization with over 8000 members from all sectors of health and social care interested in disability and oral health who work to share their scientific knowledge, research, clinical skills and collective experience to reduce barriers to care and improve oral health outcomes for people with disability.
For more information, please visit: https://www.oralb.co.uk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006117/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom